

Supplementary file

Biological relevance of the modules identified for Dataset II

Visualization of identified modules is showed in Figures S4-S5. Many core regulators and regulatory relationships have been verified by other literatures. For example, has-mR-15a that appeared in two identified modules was identified as regulators in multiple cancer types. It was shown that has-miR-15a was down-regulated in the majority of non-small cell lung cancer to induce cell cycle arrest in G1-G0 in a Rb-dependent manner [1]. A study on kidney cancer also suggested has-miR-15a may be involved in cancer pathogenesis and has the potential to be biomarkers [2]. Another research proposed that miR-15a acted as tumor suppressor genes in prostate cancer through the control of cell survival, proliferation and invasion [3]. A research using breast cancer samples validated this conclusion by showing that has-miR-15a can suppress cancer stem cells growth and hypothesizing it may play a pivotal role in multiple cancers [4]. Bhattacharya revealed possible development of therapeutic strategies by restoring has-miR-15a expression in ovarian cancer and in other cancers [5]. Similarly, has-miR-19a was identified as a core regulator in 4 identified modules, its expression was also found significantly associated with colorectal cancer [6], lung cancer [7] and multiple myeloma [8]. Another study demonstrated hsa-miR-19b as co-regulator with has-miR-19a in regulating the IL-6 antiapoptotic signaling in the pathogenesis and malignant growth of multiple myeloma [8].

Besides core microRNAs, core transcription factors in our identified modules are verified to be relevant with multiple cancers as well. For example, ARNT2, aryl hydrocarbon receptor nuclear translocator, was annotated as a pivot gene in cancer related pathways by KEGG. And many studies have showed that its differential expression maybe associated with disease outcome of colon cancer [9] and lung carcinoma [10]. However its regulatory mechanism has not been well explored by available researches. Its involvement in three identified modules may provide guidance for further experimental design. SMAD3, an intracellular signal transducer and transcriptional modulator, was found overexpressed in advanced human prostate cancer and critical for progression of prostate cancer cells [11]. And our identified modules suggest it may also promote the progressive growth of other type of tumor cells. TP53 (p53) is a well-explored gene that regulates a large number of genes and thus controls a number of key tumor suppressing functions such as cell cycle arrest, DNA repair, senescence and apoptosis. TP53 was identified as core transcription factor regulators in module 2, 7, and 10. Even it was not differentially expressed based on stringent p value cutoff, its positive correlation with the regulated genes suggested that its inactivation may lead to tumor progression. Similarly, MYB is another famous oncogene that plays an essential role in the regulation of hematopoiesis and may play a role in tumorigenesis [12]. Our regulatory module 3 suggests its responsibility for overall under-expression of regulated genes. GPR17, the overexpressed nTF-gene in module 4, is a Gi-coupled orphan receptor and its activation may lead to both adenylyl cyclase inhibition and intracellular calcium increase, which is also important in cell proliferation, differentiation, apoptosis, and cytotoxicity [13].

Supplementary Tables

Table S1: Summary of filtering steps for PCC by P-value cutoff

| P value threshold | # of microRNA pairs / # of microRNAs | # of microRNA-mRNA pairs/ # of microRNAs/ # of mRNAs | # of mRNA-mRNA pairs/ # of mRNAs |
|-------------------|--------------------------------------|--|----------------------------------|
| Before Filtering | 20,736 / 144 | 305,568 / 144 / 2122 | 4,502,884 / 2122 |
| P value < 0.01 | 12,390 / 144 | 150,151 / 144 / 2122 | 3,298,516 / 2122 |
| P value < 0.001 | 9,987 / 144 | 106,142 / 144 / 2122 | 2,838,129 / 2122 |
| P value < 0.0001* | 8,561 / 144 | 80,429 / 144 / 2078 | 2,495,043 / 2122 |

Table S2. Summary of filtering steps for TF predicted targeting by similarity score cutoff

| Score Threshold | # of Interactions | # of TFs / # of Targets |
|------------------|-------------------|-------------------------|
| Before filtering | 3,469,371 | 265/21,054 |
| > 0.85 | 3,359,558 | 265/21,054 |
| > 0.90 | 3,133,653 | 265/21,054 |
| > 0.95 | 2,631,890 | 262/21,054 |
| > 0.99* | 1,705,837 | 260/21,054 |
| > 0.999 | 610,465 | 242/21,054 |

Table S3. Convergence rates for different GA parameters

| Pco | Rates | Pmu | Rates | Pnew | Rates |
|------|----------|---------|----------|--------|----------|
| 0.5 | 2.27E-04 | 0.01 | 5.09E-05 | 0.01* | 3.15E-04 |
| 0.6 | 2.45E-04 | 0.001 | 2.63E-04 | 0.001 | 2.71E-04 |
| 0.7* | 3.84E-04 | 0.0001* | 1.02E-03 | 0.0001 | 2.81E-04 |
| 0.8 | 2.69E-04 | 0.00001 | 4.97E-04 | | |
| 0.9 | 2.61E-4 | | | | |

Table S4 (A): Identified modules in dataset I

| ID | microRNA | TF | nTF | Score | P value |
|----|--|---|---|--------|----------|
| 1 | hsa-miR-382 hsa-miR-520d-3p hsa-miR-645 | EGR3,HA ND1,POU2 F2,RFX3,S OX9,SP3,T CF7 | ANXA6,ATP2B4,CCND2, CHRDL1,CNN1,CXCL11, DPYSL3,EGR2,FLNA,JA ZF1,LMOD1,MSRB3,MY LK,RBPMS,SLC8A1,SOR BS1,SVIL,TAGLN,TNS1, TPM1,TSPAN18,VCL | 0.8386 | 3.40E-03 |
| 2 | hsa-miR-382 hsa-miR-423-3p hsa-miR-520d-3p | MEIS1,RF X3,SOX9 | ACTA2,ATP2B4,CALD1, CAP2,CAV1,CCND2,CD C42EP3,CFL2,CHRDL1,C LU,CNN1,CORO1C,DDR 2,DMD,DPYSL3,FHL1,FL NA,FRMD6,LMOD1,MA P1B,MSRB3,MYL9,MYL K,MYOCD,PALLD,PCP4, RBPMS,SEC23A,SLC8A1 ,SORBS1,SVIL,TIMP2,TL N1,TNS1,TPM1,VCL | 0.8574 | 2.50E-03 |
| 3 | hsa-miR-129-5p hsa-miR-328 hsa-miR-645 | EGR3,IRF 1,POU3F1, RFX3,RU NX3,SOX9 ,TOPORS | ACTN1,AHNAK2,ANXA 6,BNC2,CHRDL1,CLU,C OL4A2,COL6A1,DES,DK K3,EDNRA,FLNA,FLNC, FZD7,GSN,HEPH,HTRA1 ,ITGA9,ITIH5,JAZF1,KC NMB1,LGALS1,LMOD1, MAP1B,MCAM,MFGE8, MRVII1,MYL9,MYLK,NI D1,PMP22,RBPMS,SLC2 4A3,SLC8A1,TIMP2,TNS 1,TPM2,TSPAN18,Wfdc 1 | 0.836 | 1.20E-03 |

Table S4 (A): Identified modules in dataset I

| ID | microRNA | TF | nTF | Score | P value |
|----|---|---|--|--------|----------|
| 4 | hsa-miR-647 hsa-miR-877* hsa-miR-885-5p | FOSL1,FO XA1,GLI1, HMGA2,J UND,MAZ ,NKX2- 5,PAX8,P DX1,RFX3 ,RUNX2,S OX9,STAT 3,T,ZBTB7 A | ASCC1,ATP6V1E1,CLAS P1,CLCA2,DCTN2,DLST, DYN1H1,FXYD6,GPX2, KIAA0430,MYST2,PARD 3,PCDH10,PPP3CB,RBM 23,SDHD,SERPINA11,SI GLEC12,TMEM132A,TO R1AIP1,ZFHX4 | 0.7608 | 2.20E-03 |
| 5 | hsa-let-7d* hsa-miR-548d-5p hsa-miR-647 | ETV4,FOS L1,GATA6 ,HAND1,R FX3,SOX9 ,STAT3 | ACTN1,ANXA6,ATP2B4, CAV1,CCND2,CNN1,CS RP1,FLNA,GSN,ILK,SOR BS1,SPTAN1,SVIL,TAGL N,TLN1,TNS1,TPM2 | 0.841 | 4.90E-03 |
| 6 | hsa-miR-10b* hsa-miR-625 hsa-miR-660 | DDIT3,HL F,MEIS1 | ACTG2,ACTN1,ANXA6, ATP2B4,CALD1,CAMK2 G,CAV1,CCND2,CHRDL 1,CLU,CNN1,CORO1C,C RYAB,CSRP1,DDR2,DES ,DPYSL3,DUSP3,EDNRA ,EYA4,FHL1,FLNA,FLN C,ILK,KCNMB1,LMOD1, MAOB,MATN2,MEIS2,M SRB3,MYLK,NEXN,NPT N,PALLD,PARVA,PPP1R 3C,PRNP,RBPMS,SLC8A 1,SVIL,TAGLN,TGFB2,T GFBR3,TIMP2,TLN1,TNS 1,TPM1,TSPAN2,VCL | 0.8194 | 3.10E-03 |

Table S4 (A): Identified modules in dataset I

| ID | microRNA | TF | nTF | Score | P value |
|----|---|--|---|--------|----------|
| 7 | hsa-miR-328 hsa-miR-605 hsa-miR-645 | MEIS1,PG R,RFX3,S REBF2 | ACTN1,ADRA1A,ANXA 6,ATP2B4,BNC2,CAV1,C HRDL1,CLU,CNN1,CNT N1,CORO1C,DDR2,DPYS L3,EDNRA,FAT4,FBN1,F LNA,GNAL,GSN,ITGB3,I TIH5,KCNMA1,LAMA4, LMOD1,MAP1B,MRVI1, MSRB3,MYH11,MYLK, MYOCD,PDZRN4,PMP22 ,RBMS2,RGN,SLC8A1,S ORBS1,SSPN,SVIL,TIMP 2,TMEM47,TNS1,TPM1,T PM2,TRPC1,TRPC4,VCL | 0.8207 | 2.50E-03 |
| 8 | hsa-let-7b* hsa-let-7d* hsa-let-7f-1* | BPTF,EGR 3,HAND1, POU3F1,R FX3,SOX9 ,TGIF1 | ADCY5,AHNAK2,CAV1, CHRDL1,CLU,CNN1,CO L4A2,COL6A1,COL6A2, DBNDD2,DES,DKK3,DN AJB5,EFEMP2,ENO2,FG FR1,FHOD3,FLNC,FZD7, GAS6,GPR124,GSN,HEP H,ITGA7,ITGA9,ITGB3,I TIH5,JAZF1,LMOD1,MA RVELD1,MCAM,MKX,M RGPRF,MRVI1,NFASC,P NMA1,PRICKLE2,RARR ES2,SLC24A3,ST5,TSPA N18,Wfdc1 | 0.8106 | 2.40E-03 |

Table S4 (A): Identified modules in dataset I

| ID | microRNA | TF | nTF | Score | P value |
|----|---|--|---|--------|----------|
| 9 | hsa-let-7b* hsa-let-7d* hsa-miR-328 | DDIT3,IRF1,JUND,M EIS1,RFX3,SOX9,ZBTB16 | ABCC9,ANXA6,ATP2B4,C20orf194,CACHD1,CALD1,CAMK2G,CAP2,CAV1,CCND2,CFL2,CLIP4,CORO1C,DDR2,DMD,DPYSL3,EDNRA,EPB41L2,FRMD6,KLHL5,LTBP1,MAP1B,MFN2,MSRB3,NT5E,PALLD,PDGFC,PLS3,PRNP,PSIP1,RBMS2,RBMS3,RBPM3,SEC23A,SLC8A1,SORBS1,SPARCL1,SPTAN1,SVIL,TEAD1,TIMP2,TLN1,TNS1,TRPC1,TRPC4,TSPAN2,VCL,WWTR1,ZNF483 | 0.8097 | 1.90E-03 |
| 10 | hsa-let-7b* hsa-let-7d* hsa-let-7f-1* | DDIT3,ELF4,ESR1,IRF1,MEIS1,NFE2L1,NR5A2 | ACSL4,C20orf194,CAP2,CDC42EP3,CDS2,CFL2,CLIC4,CLIP4,CNTN1,CORO1C,CRYAB,CSRP1,DPYSL3,DUSP3,EPB41L2,FA M92A1,FCGBP,HECTD2,ITSN1,JAK1,KPNA3,LPP,MBNL2,MEIS2,NEXN,NPTN,PALLD,PBX1,PCDH18,PDGFC,PIK3R1,PLS3,PLSCR4,PPP1R12A,PRNP,PRRT2,PSIP1,PTPLA,RBM9,RBMS3,RNF180,RSU1,SEC23A,SLC8A1,SORB1,SPTAN1,TEAD1,TLN1,TPM1,TRPC1,VCL,WWT1,ZNF483 | 0.7718 | 3.50E-03 |

Table S4 (B): Enriched KEGG pathways of identified modules in dataset I

| Module ID | KEGG pathways | P value |
|-----------|---|-------------|
| 1 | hsa04510:Focal adhesion | 0.004283822 |
| | hsa04520:Adherens junction | 0.007606025 |
| | hsa04020:Calcium signaling pathway | 0.036540214 |
| 2 | hsa04510:Focal adhesion | 8.16E-06 |
| | hsa04270:Vascular smooth muscle contraction | 0.003171875 |
| | hsa04810:Regulation of actin cytoskeleton | 0.019206274 |
| | hsa05410:Hypertrophic cardiomyopathy (HCM) | 0.022059277 |
| | hsa05414:Dilated cardiomyopathy | 0.025583328 |
| 3 | hsa04510:Focal adhesion | 6.68E-07 |
| | hsa04270:Vascular smooth muscle contraction | 2.52E-04 |
| | hsa05412:Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 0.001283014 |
| | hsa05410:Hypertrophic cardiomyopathy (HCM) | 0.001774001 |
| | hsa05414:Dilated cardiomyopathy | 0.002227637 |
| | hsa04810:Regulation of actin cytoskeleton | 0.002935721 |
| | hsa04512:ECM-receptor interaction | 0.024629357 |
| 4 | NA | NA |
| 5 | hsa04510:Focal adhesion | 5.80E-05 |
| 6 | hsa04510:Focal adhesion | 1.54E-07 |
| | hsa04270:Vascular smooth muscle contraction | 0.001686291 |
| | hsa05410:Hypertrophic cardiomyopathy (HCM) | 0.007080857 |
| | hsa04020:Calcium signaling pathway | 0.008566318 |
| | hsa05414:Dilated cardiomyopathy | 0.008810366 |
| | hsa04010:MAPK signaling pathway | 0.034423309 |
| | hsa05412:Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 0.04922478 |
| 7 | hsa04020:Calcium signaling pathway | 5.56E-05 |
| | hsa04270:Vascular smooth muscle contraction | 7.28E-05 |
| | hsa04510:Focal adhesion | 1.17E-04 |
| | hsa05410:Hypertrophic cardiomyopathy (HCM) | 0.004823721 |
| | hsa05414:Dilated cardiomyopathy | 0.0060202 |
| | hsa04810:Regulation of actin cytoskeleton | 0.010549498 |
| | hsa05412:Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 0.038540555 |
| | hsa04520:Adherens junction | 0.039470992 |
| | hsa04260:Cardiac muscle contraction | 0.040410096 |

Table S4 (B): Enriched KEGG pathways of identified modules in dataset I

| Module ID | KEGG pathways | P value |
|-----------|---|-------------|
| 8 | hsa04510:Focal adhesion | 1.15E-06 |
| | hsa04512:ECM-receptor interaction | 4.13E-06 |
| | hsa05414:Dilated cardiomyopathy | 1.55E-04 |
| | hsa05412:Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 0.0015622 |
| | hsa05410:Hyperrophic cardiomyopathy (HCM) | 0.002157177 |
| | hsa04810:Regulation of actin cytoskeleton | 0.003786154 |
| 9 | hsa04020:Calcium signaling pathway | 0.006223127 |
| | hsa04510:Focal adhesion | 0.009899224 |
| 10 | hsa04510:Focal adhesion | 0.006973886 |
| | hsa04810:Regulation of actin cytoskeleton | 0.008826945 |

Table S4 (C): Enriched GO terms of identified modules in dataset I

| ID | Term | Count | Fold Enrichment | Benjamini | FDR |
|----|---|-------|-----------------|-----------|----------|
| 1 | GO:0003779~actin binding | 9 | 13.275051 | 1.65E-05 | 1.72E-04 |
| | GO:0008092~cytoskeletal protein binding | 10 | 9.5407113 | 1.74E-05 | 3.63E-04 |
| 2 | GO:0003779~actin binding | 16 | 18.20578 | 1.13E-13 | 1.03E-12 |
| | GO:0008092~cytoskeletal protein binding | 18 | 13.247959 | 6.34E-14 | 1.15E-12 |
| | GO:0005856~cytoskeleton | 19 | 5.3289886 | 5.73E-08 | 4.61E-07 |
| | GO:0015629~actin cytoskeleton | 11 | 15.838909 | 4.58E-08 | 7.37E-07 |
| | GO:0007010~cytoskeleton organization | 12 | 10.950890 | 2.60E-06 | 5.33E-06 |
| | GO:0043228~non-membrane-bounded organelle | 21 | 3.1332819 | 1.17E-05 | 2.81E-04 |
| | GO:0043232~intracellular non-membrane-bounded organelle | 21 | 3.1332819 | 1.17E-05 | 2.81E-04 |
| | GO:0030055~cell-substrate junction | 6 | 20.75 | 2.91E-04 | 0.00937 |
| | GO:0044449~contractile fiber part | 6 | 20.566371 | 2.43E-04 | 0.00979 |
| | GO:0043292~contractile fiber | 6 | 19.206611 | 2.83E-04 | 0.01368 |
| | GO:0006937~regulation of muscle contraction | 5 | 27.630718 | 0.0099143 | 0.04080 |
| | GO:0005924~cell-substrate adherens junction | 5 | 18.270440 | 0.0028371 | 0.15997 |
| | GO:0016323~basolateral plasma membrane | 6 | 11.448275 | 0.0025243 | 0.16264 |
| | GO:0005912~adherens junction | 5 | 12.494623 | 0.0084641 | 0.68192 |
| 3 | GO:0003779~actin binding | 8 | 8.6108439 | 0.0035730 | 0.03089 |
| | GO:0008092~cytoskeletal protein binding | 9 | 6.2659266 | 0.0038333 | 0.06628 |
| 4 | GO:0043565~sequence-specific DNA binding | 13 | 8.4258898 | 1.02E-06 | 1.06E-05 |
| | GO:0045944~positive regulation of transcription from RNA polymerase II promoter | 10 | 11.394878 | 6.03E-05 | 1.40E-04 |
| | GO:0003700~transcription factor activity | 14 | 5.6491686 | 1.10E-05 | 2.27E-04 |
| | GO:0006357~regulation of transcription from RNA polymerase II promoter | 12 | 6.9779917 | 1.01E-04 | 4.70E-04 |
| | GO:0045893~positive regulation of transcription, DNA-dependent | 10 | 8.8626834 | 1.68E-04 | 0.00117 |
| | GO:0051254~positive regulation of RNA metabolic process | 10 | 8.7889812 | 1.35E-04 | 0.00125 |

Table S4 (C): Enriched GO terms of identified modules in dataset I

| ID | Term | Count | Fold Enrichment | Benjamini | FDR |
|----|---|-------|-----------------|-----------|----------|
| 4 | GO:0006355~regulation of transcription, DNA-dependent | 16 | 3.8150028 | 2.66E-04 | 0.00309 |
| | GO:0051252~regulation of RNA metabolic process | 16 | 3.7308328 | 2.95E-04 | 0.00411 |
| | GO:0006350~transcription | 17 | 3.4206330 | 2.88E-04 | 0.00469 |
| | GO:0045941~positive regulation of transcription | 10 | 7.4955673 | 2.53E-04 | 0.00470 |
| | GO:0010628~positive regulation of gene expression | 10 | 7.2762478 | 2.87E-04 | 0.00600 |
| | GO:0030528~transcription regulator activity | 15 | 3.9030182 | 1.78E-04 | 0.00551 |
| | GO:0045935~positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | 10 | 6.7748397 | 4.62E-04 | 0.01075 |
| | GO:0051173~positive regulation of nitrogen compound metabolic process | 10 | 6.5644409 | 5.42E-04 | 0.01387 |
| | GO:0010557~positive regulation of macromolecule biosynthetic process | 10 | 6.4640672 | 5.62E-04 | 0.01571 |
| | GO:0045449~regulation of transcription | 18 | 2.9256055 | 5.23E-04 | 0.01582 |
| | GO:0031328~positive regulation of cellular biosynthetic process | 10 | 6.1715328 | 7.00E-04 | 0.022806 |
| | GO:0009891~positive regulation of biosynthetic process | 10 | 6.0827338 | 7.33E-04 | 0.02561 |
| | GO:0003677~DNA binding | 17 | 2.8692458 | 9.81E-04 | 0.04059 |
| | GO:0016563~transcription activator activity | 8 | 7.6765705 | 0.0011010 | 0.05698 |
| | GO:0016481~negative regulation of transcription | 8 | 7.3681917 | 0.0025603 | 0.09544 |
| 5 | GO:0010604~positive regulation of macromolecule metabolic process | 10 | 4.9329054 | 0.0033599 | 0.13311 |
| | GO:0010629~negative regulation of gene expression | 8 | 6.7103174 | 0.0040925 | 0.17170 |
| | GO:0045934~negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | 8 | 6.6054687 | 0.0042769 | 0.18940 |
| | GO:0051172~negative regulation of nitrogen compound metabolic process | 8 | 6.5163776 | 0.0044211 | 0.20609 |

Table S4 (C): Enriched GO terms of identified modules in dataset I

| ID | Term | Count | Fold Enrichment | Benjamini | FDR |
|----|--|-------|-----------------|-----------|----------|
| 5 | GO:0010558~negative regulation of macromolecule biosynthetic process | 8 | 6.1828153 | 0.0058264 | 0.28527 |
| | GO:0031327~negative regulation of cellular biosynthetic process | 8 | 6.0285204 | 0.0064962 | 0.33324 |
| | GO:0009890~negative regulation of biosynthetic process | 8 | 5.9022687 | 0.0070736 | 0.37938 |
| | GO:0003702~RNA polymerase II transcription factor activity | 6 | 9.6743666 | 0.0054231 | 0.33705 |
| | GO:0003779~actin binding | 11 | 18.253195 | 7.14E-09 | 8.19E-08 |
| | GO:0008092~cytoskeletal protein binding | 11 | 11.806630 | 2.48E-07 | 5.69E-06 |
| | GO:0005912~adherens junction | 7 | 28.862580 | 7.77E-06 | 7.80E-05 |
| | GO:0070161~anchoring junction | 7 | 26.009883 | 7.21E-06 | 1.45E-04 |
| | GO:0005924~cell-substrate adherens junction | 6 | 36.175471 | 1.42E-05 | 4.29E-04 |
| | GO:0030055~cell-substrate junction | 6 | 34.2375 | 1.41E-05 | 5.65E-04 |
| | GO:0015629~actin cytoskeleton | 7 | 16.630855 | 4.00E-05 | 0.00201 |
| | GO:0007010~cytoskeleton organization | 8 | 10.792181 | 0.0029277 | 0.00588 |
| | GO:0043232~intracellular non-membrane-bounded organelle | 14 | 3.4466101 | 1.44E-04 | 0.00866 |
| | GO:0043228~non-membrane-bounded organelle | 14 | 3.4466101 | 1.44E-04 | 0.00866 |
| | GO:0016323~basolateral plasma membrane | 6 | 18.889655 | 1.51E-04 | 0.01059 |
| | GO:0005925~focal adhesion | 5 | 31.328431 | 1.91E-04 | 0.01534 |
| | GO:0030016~myofibril | 5 | 28.788288 | 2.37E-04 | 0.02143 |
| | GO:0044449~contractile fiber part | 5 | 28.278761 | 2.29E-04 | 0.02300 |
| | GO:0030036~actin cytoskeleton organization | 6 | 15.615236 | 0.0065640 | 0.03962 |
| | GO:0043292~contractile fiber | 5 | 26.409090 | 2.73E-04 | 0.03012 |
| | GO:0030029~actin filament-based process | 6 | 14.643333 | 0.0067001 | 0.05393 |
| | GO:0010604~positive regulation of macromolecule metabolic process | 9 | 6.1768555 | 0.0054772 | 0.05507 |
| | GO:0005856~cytoskeleton | 10 | 4.6278059 | 6.20E-04 | 0.07472 |
| | GO:0030054~cell junction | 7 | 8.6364864 | 6.46E-04 | 0.08437 |
| | GO:0019900~kinase binding | 5 | 15.110567 | 0.0080340 | 0.27725 |
| 6 | GO:0008092~cytoskeletal protein binding | 19 | 9.7887698 | 2.02E-11 | 1.39E-10 |
| | GO:0003779~actin binding | 16 | 12.744049 | 4.73E-11 | 6.48E-10 |

Table S4 (C): Enriched GO terms of identified modules in dataset I

| ID | Term | Count | Fold Enrichment | Benjamini | FDR |
|----|---|-------|-----------------|-----------|----------|
| 6 | GO:0044449~contractile fiber part | 9 | 23.675241 | 4.22E-07 | 3.22E-06 |
| | GO:0043292~contractile fiber | 9 | 22.109936 | 3.64E-07 | 5.55E-06 |
| | GO:0005924~cell-substrate | | | | |
| | adherens junction | 8 | 22.434401 | 2.47E-06 | 5.65E-05 |
| | GO:0030016~myofibril | 8 | 21.423842 | 2.55E-06 | 7.79E-05 |
| | GO:0030055~cell-substrate | | | | |
| | junction | 8 | 21.232558 | 2.17E-06 | 8.29E-05 |
| | GO:0005856~cytoskeleton | 19 | 4.0896889 | 2.65E-06 | 1.21E-04 |
| | GO:0007010~cytoskeleton | | | | |
| | organization | 12 | 7.9219207 | 1.60E-04 | 2.61E-04 |
| | GO:0015629~actin cytoskeleton | 10 | 11.050402 | 3.88E-06 | 2.07E-04 |
| | GO:0005912~adherens junction | 8 | 15.342235 | 1.26E-05 | 7.66E-04 |
| | | | | | 0.001115 |
| | GO:0005925~focal adhesion | 7 | 20.399908 | 1.62E-05 | 136 |
| | | | | | 0.001545 |
| | GO:0070161~anchoring junction | 8 | 13.825851 | 2.03E-05 | 463 |
| | GO:0016323~basolateral plasma membrane | 8 | 11.714514 | 5.56E-05 | 0.004662 |
| | GO:0007517~muscle organ development | 8 | 10.912977 | 0.0031345 | 0.010214 |
| | GO:0006936~muscle contraction | 7 | 13.168683 | 0.0039353 | 0.019243 |
| | GO:0003012~muscle system process | 7 | 11.992907 | 0.0050215 | 0.032755 |
| | GO:0034330~cell junction organization | 5 | 25.248226 | 0.0078042 | 0.063712 |
| | GO:0051270~regulation of cell motion | 7 | 10.439422 | 0.0072990 | 0.071485 |
| | GO:0005886~plasma membrane | 26 | 2.0462407 | 6.68E-04 | 0.061088 |
| | GO:0051271~negative regulation of cell motion | 5 | 22.843633 | 0.0082799 | 0.09464 |
| | GO:0010035~response to inorganic substance | 7 | 9.8283341 | 0.0076594 | 0.10002 |
| | GO:0044057~regulation of system process | 8 | 7.4519038 | 0.0080802 | 0.11872 |
| | GO:0043228~non-membrane-bounded organelle | 20 | 2.2901064 | 0.0027969 | 0.27728 |
| | GO:0043232~intracellular non-membrane-bounded organelle | 20 | 2.2901064 | 0.0027969 | 0.27728 |
| | GO:0030017~sarcomere | 5 | 15.166112 | 0.0032775 | 0.34988 |
| | GO:0044459~plasma membrane part | 18 | 2.4287810 | 0.0033480 | 0.3828 |
| 7 | GO:0003779~actin binding | 15 | 13.892495 | 1.43E-10 | 1.03E-09 |

Table S4 (C): Enriched GO terms of identified modules in dataset I

| ID | Term | Count | Fold Enrichment | Benjamini | FDR |
|----|--|-------|-----------------|-----------|----------|
| 7 | GO:0008092~cytoskeletal protein binding | 16 | 9.5850867 | 1.78E-09 | 2.55E-08 |
| | GO:0044449~contractile fiber part | 7 | 19.312324 | 2.18E-04 | 0.00153 |
| | GO:0015629~actin cytoskeleton | 9 | 10.430501 | 1.29E-04 | 0.00182 |
| | GO:0043292~contractile fiber | 7 | 18.035476 | 1.09E-04 | 0.00229 |
| | GO:0044459~plasma membrane part | 21 | 2.9718012 | 8.65E-05 | 0.00243 |
| | GO:0006937~regulation of muscle contraction | 6 | 25.051851 | 0.0029300 | 0.0053 |
| | GO:0010035~response to inorganic substance | 8 | 11.731598 | 0.0016872 | 0.00611 |
| | GO:0007010~cytoskeleton organization | 10 | 6.895005 | 0.0025599 | 0.01391 |
| | GO:0034329~cell junction assembly | 5 | 36.661246 | 0.0019304 | 0.01398 |
| | GO:0006936~muscle contraction | 7 | 13.753957 | 0.0016066 | 0.01454 |
| | GO:0005886~plasma membrane | 26 | 2.1460573 | 5.38E-04 | 0.01892 |
| | GO:0003012~muscle system process | 7 | 12.525925 | 0.0022827 | 0.02480 |
| | GO:0005509~calcium ion binding | 13 | 4.2710479 | 0.0012661 | 0.02727 |
| | GO:0030016~myofibril | 6 | 16.851680 | 6.75E-04 | 0.02853 |
| | GO:0034330~cell junction organization | 5 | 26.370370 | 0.0041383 | 0.0525 |
| | GO:0005856~cytoskeleton | 15 | 3.3861994 | 0.0010574 | 0.05211 |
| | GO:0044057~regulation of system process | 8 | 7.7830996 | 0.0053322 | 0.08701 |
| | GO:0051924~regulation of calcium ion transport | 5 | 21.784219 | 0.0061565 | 0.11166 |
| | GO:0030036~actin cytoskeleton organization | 7 | 9.3113077 | 0.0065518 | 0.13073 |
| | GO:0006816~calcium ion transport | 6 | 12.702347 | 0.0065963 | 0.14357 |
| | GO:0030029~actin filament-based process | 7 | 8.7317657 | 0.0078895 | 0.18611 |
| | GO:0010959~regulation of metal ion transport | 5 | 18.556927 | 0.0082182 | 0.20879 |
| | GO:0048471~perinuclear region of cytoplasm | 7 | 7.5774051 | 0.0054274 | 0.30598 |
| | GO:0005924~cell-substrate adherens junction | 5 | 14.705476 | 0.0062559 | 0.39677 |
| | GO:0030055~cell-substrate junction | 5 | 13.917682 | 0.0069428 | 0.48920 |
| | GO:0016323~basolateral plasma membrane | 6 | 9.2144659 | 0.0063514 | 0.49213 |

Table S4 (C): Enriched GO terms of identified modules in dataset I

| ID | Term | Count | Fold Enrichment | Benjamini | FDR |
|----|---|-------|-----------------|-----------|----------|
| 9 | GO:0003779~actin binding | 16 | 12.022687 | 2.29E-10 | 1.69E-09 |
| | GO:0008092~cytoskeletal protein binding | 17 | 8.2626160 | 4.90E-09 | 7.25E-08 |
| | GO:0006816~calcium ion transport | 8 | 16.215762 | 3.84E-04 | 7.10E-04 |
| | GO:0005856~cytoskeleton | 18 | 3.7022447 | 2.10E-04 | 0.00161 |
| | GO:0007010~cytoskeleton organization | 11 | 7.2617606 | 6.55E-04 | 0.00242 |
| | GO:0015674~di-, tri-valent inorganic cation transport | 8 | 13.083172 | 5.43E-04 | 0.00301 |
| | GO:0043228~non-membrane-bounded organelle | 23 | 2.5165725 | 5.53E-04 | 0.01272 |
| | GO:0043232~intracellular non-membrane-bounded organelle | 23 | 2.5165725 | 5.53E-04 | 0.01272 |
| | GO:0015629~actin cytoskeleton | 8 | 8.4474184 | 0.0013057 | 0.04005 |
| | GO:0030055~cell-substrate junction | 6 | 15.216666 | 0.0012255 | 0.04699 |
| | GO:0016323~basolateral plasma membrane | 7 | 9.7946360 | 0.0016633 | 0.07654 |
| | GO:0045121~membrane raft | 6 | 11.917948 | 0.0027978 | 0.1502 |
| | GO:0005912~adherens junction | 6 | 10.995268 | 0.0035711 | 0.21916 |
| | GO:0070161~anchoring junction | 6 | 9.9085271 | 0.0051448 | 0.35525 |
| | GO:0005886~plasma membrane | 25 | 1.8800929 | 0.0070906 | 0.54403 |
| | GO:0005924~cell-substrate adherens junction | 5 | 13.398322 | 0.0066870 | 0.56419 |
| | GO:0030016~myofibril | 5 | 12.794794 | 0.0072964 | 0.67142 |
| | GO:0044449~contractile fiber part | 5 | 12.568338 | 0.0072053 | 0.71809 |
| | GO:0043292~contractile fiber | 5 | 11.737373 | 0.0080736 | 0.92784 |
| 10 | GO:0008092~cytoskeletal protein binding | 15 | 7.2905435 | 1.07E-06 | 8.10E-06 |
| | GO:0003779~actin binding | 12 | 9.0170158 | 4.05E-06 | 6.14E-05 |
| | GO:0015629~actin cytoskeleton | 10 | 11.050402 | 2.67E-05 | 2.07E-04 |
| | GO:0005856~cytoskeleton | 15 | 3.2287018 | 0.0060867 | 0.09456 |
| | GO:0005912~adherens junction | 6 | 11.506676 | 0.0074944 | 0.17470 |
| | GO:0070161~anchoring junction | 6 | 10.369388 | 0.0091294 | 0.28383 |
| | GO:0044449~contractile fiber part | 5 | 13.152912 | 0.0096490 | 0.59918 |
| | GO:0016323~basolateral plasma membrane | 6 | 8.7858861 | 0.0087032 | 0.60769 |
| | GO:0043292~contractile fiber | 5 | 12.283298 | 0.0099924 | 0.77509 |

Table S4 (D): Identified modules using negative PCC of miRNA-mRNA in dataset I

| ID | microRNA | TF | nTF | Score | P value |
|----|---|---|---|--------|----------|
| 1 | hsa-let-7e* hsa-miR-181c* hsa-miR-196a | HAND1,J UND,RFX 3,SOX9,SP 3,SREBF2, TCF7 | ANXA6,ATP2B4,CCND2, CHRDL1,CNN1,CXCL11, DPYSL3,EGR2,FLNA,JA ZF1,LMOD1,MSRB3,MY LK,RBPMS,SLC8A1,SOR BS1,SVIL,TAGLN,TNS1, TPM1,TSPAN18,VCL | 0.8652 | 1.90E-03 |
| 2 | hsa-miR-136 hsa-miR-198 hsa-miR-383 | MEIS1,RF X3,SOX9 | ACTA2,ATP2B4,CALD1, CAP2,CAV1,CCND2,CD C42EP3,CFL2,CHRDL1,C LU,CNN1,CORO1C,DDR 2,DMD,DPYSL3,FHL1,FL NA,FRMD6,LMOD1,MA P1B,MSRB3,MYL9,MYL K,MYOCD,PALLD,PCP4, RBPMS,SEC23A,SLC8A1 ,SORBS1,SVIL,TIMP2,TL N1,TNS1,TPM1,VCL | 0.896 | 1.00E-03 |
| 3 | hsa-miR-181c* hsa-miR-193a-5p hsa-miR-383 | FOSL1,HA ND1,JUN D,NFE2L1, NFKB2,R UNX3,ST AT3 | ACTN1,AHNAK2,ANXA 6,BNC2,CHRDL1,CLU,C OL4A2,COL6A1,DES,DK K3,EDNRA,FLNA,FLNC, FZD7,GSN,HEPH,HTRA1 ,ITGA9,ITIH5,JAZF1,KC NMB1,LGALS1,LMOD1, MAP1B,MCAM,MFGE8, MRVII1,MYL9,MYLK,NI D1,PMP22,RBPMS,SLC2 4A3,SLC8A1,TIMP2,TNS 1,TPM2,TSPAN18,Wfdc 1 | 0.865 | 1.10E-03 |
| 4 | hsa-let-7e* hsa-miR-885-5p | ELF4,HAN D1,HNF4A ,NFATC2, NFE2L3,R FX3,SOX9 | ASCC1,ATP6V1E1,CLAS P1,CLCA2,DCTN2,DLST, DYN1H1,FXYD6,GPX2, KIAA0430,MYST2,PARD 3,PCDH10,PPP3CB,RBM 23,SDHD,SERPINA11,SI GLEC12,TMEM132A,TO R1AIP1,ZFHX4 | 0.8255 | 1.00E-03 |

Table S4 (D): Identified modules in dataset I

| ID | microRNA | TF | nTF | Score | P value |
|----|---|------------------------------------|---|--------|----------|
| 5 | hsa-miR-101* hsa-miR-136* | RFX3,SOX9 | ACTN1,ANXA6,ATP2B4,CAV1,CCND2,CNN1,CSRP1,FLNA,GSN,ILK,SORBS1,SPTAN1,SVIL,TAGLN,TLN1,TNS1,TPM2 | 0.8844 | 3.60E-03 |
| 6 | hsa-miR-101* hsa-miR-196a hsa-miR-198 | HOXA7,M EIS1,RFX3 ,SOX9,ZEB1 | ACTG2,ACTN1,ANXA6,ATP2B4,CALD1,CAMK2G,CAV1,CCND2,CHRDL1,CLU,CNN1,CORO1C,CRYAB,CSRP1,DDR2,DES,DPYSL3,DUSP3,EDNRA,EYA4,FHL1,FLNA,FLNC,ILK,KCNMB1,LMOD1,MAOB,MATN2,MEIS2,M,SRB3,MYLK,NEXN,NPTN,PALLD,PARVA,PPP1R3C,PRNP,RBPMS,SLC8A1,SVIL,TAGLN,TGFB2,TGFBR3,TIMP2,TLN1,TNS1,TPM1,TSPAN2,VCL | 0.8714 | 1.40E-03 |
| 7 | hsa-miR-198 hsa-miR-335* | SOX9 | ACTN1,ADRA1A,ANXA6,ATP2B4,BNC2,CAV1,C,HRDL1,CLU,CNN1,CNTN1,CORO1C,DDR2,DPYSL3,EDNRA,FAT4,FBN1,FLNA,GNAL,GSN,ITGB3,I,TIH5,KCNMA1,LAMA4,LMOD1,MAP1B,MRVI1,MSRB3,MYH11,MYLK,MYOCD,PDZRN4,PMP22,RBMS2,RGN,SLC8A1,SORBS1,SSPN,SVIL,TIMP2,TMEM47,TNS1,TPM1,TPM2,TRPC1,TRPC4,VCL | 0.8924 | 4.00E-04 |

Table S4 (D): Identified modules in dataset I

| ID | microRNA | TF | nTF | Score | P value |
|----|--|---|---|--------|----------|
| 8 | hsa-miR-136 hsa-miR-193a-5p hsa-miR-214* | EGR3,FOS L1,HAND 1,IRF4,PO U4F1,SOX 9,TGIF1 | ADCY5,AHNAK2,CAV1, CHRDL1,CLU,CNN1,CO L4A2,COL6A1,COL6A2, DBNDD2,DES,DKK3,DN AJB5,EFEMP2,ENO2,FG FR1,FHOD3,FLNC,FZD7, GAS6,GPR124,GSN,HEP H,ITGA7,ITGA9,ITGB3,I TIH5,JAZF1,LMOD1,MA RVELD1,MCAM,MKX,M RGPRF,MRVI1,NFASC,P NMA1,PRICKLE2,RARR ES2,SLC24A3,ST5,TSPA N18,Wfdc1 | 0.8576 | 5.00E-04 |
| 9 | hsa-miR-155 hsa-miR-27b* | | ABCC9,ANXA6,ATP2B4, C20orf194,CACHD1,CAL D1,CAMK2G,CAP2,CAV 1,CCND2,CFL2,CLIP4,C ORO1C,DDR2,DMD,DPY SL3,EDNRA,EPB41L2,FR MD6,KLHL5,LTBP1,MA P1B,MFN2,MSRB3,NT5E ,PALLD,PDGFC,PLS3,PR NP,PSIP1,RBMS2,RBMS3 ,RBPM3,SEC23A,SLC8A 1,SORBS1,SPARCL1,SPT AN1,SVIL,TEAD1,TIMP2 ,TLN1,TNS1,TRPC1,TRP C4,TSPAN2,VCL,WWTR 1,ZNF483 | 0.8871 | 5.00E-04 |

Table S4 (D): Identified modules in dataset I

| ID | microRNA | TF | nTF | Score | P value |
|----|--|--|--|-------|----------|
| 10 | hsa-let-7f-1* hsa-miR-133b hsa-miR-625 | ESR1,IRF1 ,MAFF,NR 5A2,RFX3, TFDP1,ZE B1 | ACSL4,C20orf194,CAP2, CDC42EP3,CDS2,CFL2,C LIC4,CLIP4,CNTN1,COR O1C,CRYAB,CSRP1,DPY SL3,DUSP3,EPB41L2,FA M92A1,FCGBP,HECTD2, ITSN1,JAK1,KPNA3,LPP, MBNL2,MEIS2,NEXN,NP TN,PALLD,PBX1,PCDH1 8,PDGFC,PIK3R1,PLS3,P LSCR4,PPP1R12A,PRNP, PRRT2,PSIP1,PTPLA,RB M9,RBMS3,RNF180,RSU 1,SEC23A,SLC8A1,SORB S1,SPTAN1,TEAD1,TLN1 ,TPM1,TRPC1,VCL,WWT R1,ZNF483 | 0.843 | 9.00E-04 |

Table S5. Summary of regulatory interactions in Dataset II

| Module ID | # Nodes ^{a)} | #Interactions ^{b)} | #PCC & Binding ^{c)} | #PCC ^{d)} | # Binding ^{e)} |
|-----------|-----------------------|-----------------------------|------------------------------|--------------------|-------------------------|
| 1 | 2/6/15 | 111 | 27 | 84 | 0 |
| 2 | 2/6/08 | 34 | 21 | 13 | 0 |
| 3 | 2/5/33 | 559 | 86 | 473 | 0 |
| 4 | 2/6/21 | 286 | 72 | 214 | 0 |
| 5 | 2/6/10 | 107 | 54 | 53 | 0 |
| 6 | 2/6/13 | 154 | 71 | 83 | 0 |
| 7 | 2/6/10 | 96 | 48 | 48 | 0 |
| 8 | 2/6/17 | 180 | 67 | 113 | 0 |
| 9 | 2/6/15 | 160 | 47 | 113 | 0 |
| 10 | 2/6/13 | 138 | 57 | 81 | 0 |

a) The numbers of miRNAs, TF-genes, nTF-genes

b) The number of interactions

c) The number of interactions with support of both significant PCC and predicted binding

d) The number of interactions with support of only significant PCC

e) The number of interactions with support of only predicted binding

Table S6 (A): Table of identified modules in dataset II

| ID | microRNA | TF | nTF | Score | P value |
|----|---------------------------------|--|---|--------|----------|
| 1 | hsa-miR-15a hsa-miR-19a | EBF1,EGR3 ,FOXA1,NF E2L3,TFAP 2C,ZBTB7 A | ADD3,ATP5A1,DNAJC3,FA BP1,ITM2B,KLHDC2,NDUF S4,PAN3,PCBP1,PCYOX1,PE RP,SACM1L,SLC26A3,SRP9, TSPYL1 | 0.8364 | 4.80E-03 |
| 2 | hsa-miR-19a hsa-miR-19b | IRF7,IRF8, MYCN,TF AP2C,TP53 ,ZBTB7A | EFHA1,PAN3,SACM1L,SEM G1,SEMG2,SLC12A3,SLC34 A1,TSPYL1 | 0.7938 | 1.50E-02 |
| 3 | hsa-miR-136 hsa-miR-15a | ETS2,HMG A1,MYB,N FE2L3,TFA P2C | ADD3,ATP5A1,C16orf61,C8o rf59,CHMP5,COL5A2,COM MD3,COX7A2L,DNAJC3,EF HA1,GBAS,ITM2B,KIAA143 0,MTCH1,NDUFA4,NDUFC1 ,NDUFS4,PAN3,PCBP1,PCY OX1,RAD51L1,SACM1L,SEP T2,SLC25A3,SRP9,SUV420H 1,TMEM123,TMEM14C,TSC 22D1,TSPYL1,USP33,VPS11, ZC3H15 | 0.8233 | 3.10E-03 |
| 4 | hsa-miR-107 hsa-miR-15a | ARNT2,HM GA1,MYB, NFE2L3,TF AP2C,ZBT B7A | C20orf30,CD164,DDX5,EFH A1,EIF4A2,FOXJ3,GPR17,KI AA1033,KLHDC2,MORF4L1, MTCH1,NPTN,PCBP1,PCNP, PERP,SLC25A3,SRP9,TMEM 14C,TSPYL1,UBE4A,ZFAND 3 | 0.8088 | 6.90E-03 |
| 5 | hsa-miR- 128a hsa-miR-132 | FOXA1,HM GA1,MYB, NHLH1,RF XAP,SMA D3 | CDKN1B,FBXL3,FUBP1,GB AS,KIAA1430,PAN3,PCYOX 1,SACM1L,TSPYL1,USP33 | 0.8177 | 7.20E-03 |
| 6 | hsa-miR-19a hsa-miR-19b | ARNT2,GA TA3,MYB, MYC,RFX AP,TCF4 | ANXA7,C20orf30,DDX5,EIF 4A2,EIF4G2,FOXJ3,ITM2B, MORF4L1,NPTN,PCNP,PCY OX1,SEPT10,TJP1 | 0.8406 | 6.00E-03 |

Table S6 (A): Table of identified modules in dataset II

| ID | microRNA | TF | nTF | Score | P value |
|----|---------------------------------|--|---|--------|--------------|
| 7 | hsa-miR-1 hsa-miR-141 | ARNT2,HM GA1,MYC, TFAP2C,TP 53,ZBTB7A | C20orf30,DDX5,FBXW11,FO XJ3,KIAA0776,MORF4L1,NP TN,PCNP,PCYOX1,PERP | 0.8117 | 7.40E- 03 |
| 8 | hsa-miR-15a hsa-miR-206 | EBF1,HMG A1,NHLH1, RFXAP,SM AD3,TFAP 2C | ADIPOR2,COL1A1,COL5A2, DDX5,DSTN,EIF4A2,FBXW1 1,GOLPH3,HIAT1,NPTN,PCB P1,PCMTD1,PCNP,PCYOX1,S EPT10,VEZF1,ZNF83 | 0.8174 | 4.00E- 03 |
| 9 | hsa-miR-141 hsa-miR- 200a | ATF6,EBF1 ,FOXA1,M YCN,TFAP 2C,ZBTB7 A | ADD3,C22orf32,FUBP1,GBAS ,HOXD11,KLHDC2,MKNK2,P AN3,PFKFB4,SACM1L,SUV4 20H1,TMBIM1,TMEM123,TS PYL1,ZC3H15 | 0.8164 | 4.80E- 03 |
| 10 | hsa-miR-19a hsa-miR-19b | ARNT2,CE BPB,HMG A1,TFAP2C ,TP53,ZBT B7A | ADD3,C16orf61,CHMP5,FOXJ 3,GBAS,GPR17,KIAA1430,KL HDC2,NDUFS4,PAN3,PERP,S ACM1L,USP33 | 0.817 | 6.20E- 03 |

Table S6 (B): GO term & KEGG pathway enrichment of identified modules in dataset II

| ID | Term and Pathway | Count | Fold Enrichment | P Value |
|----|---|-------|-----------------|----------|
| 1 | GO:0003700~transcription factor activity | 6 | 4.44 | 0.006825 |
| | GO:0030528~transcription regulator activity | 7 | 3.34 | 0.009808 |
| 2 | GO:0006357~regulation of transcription from RNA polymerase II promoter | 6 | 8.59 | 0.000255 |
| | GO:0000122~negative regulation of transcription from RNA polymerase II promoter | 4 | 15.65 | 0.001450 |
| | GO:0045892~negative regulation of transcription, DNA-dependent | 4 | 11.69 | 0.003331 |
| | GO:0051253~negative regulation of RNA metabolic process | 4 | 11.50 | 0.003493 |
| | GO:0016481~negative regulation of transcription | 4 | 9.07 | 0.006792 |
| | GO:0030528~transcription regulator activity | 6 | 3.96 | 0.008331 |
| | GO:0010629~negative regulation of gene expression | 4 | 8.26 | 0.008795 |
| | GO:0045934~negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | 4 | 8.13 | 0.009184 |
| | GO:0051172~negative regulation of nitrogen compound metabolic process | 4 | 8.02 | 0.009533 |
| | GO:0003700~transcription factor activity | 5 | 5.12 | 0.009600 |
| 3 | GO:0005743~mitochondrial inner membrane | 7 | 11.25 | 0.000022 |
| | GO:0019866~organelle inner membrane | 7 | 10.46 | 0.000033 |
| | GO:0031966~mitochondrial membrane | 7 | 8.73 | 0.000089 |
| | GO:0044455~mitochondrial membrane part | 5 | 19.66 | 0.000094 |
| | hsa05012:Parkinson's disease | 5 | 16.55 | 0.000110 |
| | hsa00190:Oxidative phosphorylation | 5 | 16.30 | 0.000117 |
| | GO:0005740~mitochondrial envelope | 7 | 8.21 | 0.000125 |
| | GO:0031090~organelle membrane | 10 | 4.49 | 0.000140 |
| | GO:0005746~mitochondrial respiratory chain | 4 | 30.73 | 0.000255 |
| | hsa05010:Alzheimer's disease | 5 | 13.00 | 0.000282 |
| | GO:0070469~respiratory chain | 4 | 26.22 | 0.000407 |
| | hsa05016:Huntington's disease | 5 | 11.77 | 0.000412 |
| | GO:0005739~mitochondrion | 9 | 4.07 | 0.000775 |
| | GO:0044429~mitochondrial part | 7 | 5.78 | 0.000822 |
| | GO:0031967~organelle envelope | 7 | 5.55 | 0.001020 |
| | GO:0031975~envelope | 7 | 5.53 | 0.001037 |
| 3 | GO:0006119~oxidative phosphorylation | 4 | 19.04 | 0.001059 |
| | GO:0006091~generation of precursor metabolites and energy | 5 | 7.45 | 0.003713 |
| 4 | GO:0030528~transcription regulator activity | 8 | 3.82 | 0.001932 |
| 5 | GO:0030528~transcription regulator activity | 7 | 4.62 | 0.001223 |
| | GO:0016563~transcription activator activity | 4 | 9.74 | 0.005561 |
| | GO:0003700~transcription factor activity | 5 | 5.12 | 0.009600 |

Table S6 (B): GO term & KEGG pathway enrichment of identified modules in dataset II

| ID | Term and Pathway | Count | Fold Enrichment | P Value |
|----|---|-------|-----------------|----------|
| 6 | GO:0030528~transcription regulator activity | 8 | 4.04 | 0.001263 |
| | GO:0008134~transcription factor binding | 5 | 7.44 | 0.003001 |
| | GO:0003700~transcription factor activity | 6 | 4.70 | 0.005130 |
| 7 | GO:0030528~transcription regulator activity | 8 | 5.72 | 0.000062 |
| | GO:0044451~nucleoplasm part | 5 | 10.47 | 0.000599 |
| | GO:0003700~transcription factor activity | 6 | 6.66 | 0.000745 |
| | GO:0045449~regulation of transcription | 9 | 3.34 | 0.000941 |
| | GO:0006350~transcription | 8 | 3.68 | 0.001557 |
| | GO:0045941~positive regulation of transcription | 5 | 8.57 | 0.001582 |
| | GO:0010628~positive regulation of gene expression | 5 | 8.32 | 0.001765 |
| | GO:0045935~positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | 5 | 7.74 | 0.002296 |
| | GO:0051173~positive regulation of nitrogen compound metabolic process | 5 | 7.50 | 0.002577 |
| | GO:0010557~positive regulation of macromolecule biosynthetic process | 5 | 7.39 | 0.002727 |
| | GO:0031981~nuclear lumen | 6 | 4.81 | 0.002877 |
| | GO:0031328~positive regulation of cellular biosynthetic process | 5 | 7.05 | 0.003228 |
| | GO:0005654~nucleoplasm | 5 | 6.59 | 0.003377 |
| | GO:0009891~positive regulation of biosynthetic process | 5 | 6.95 | 0.003402 |
| | GO:0006355~regulation of transcription, DNA-dependent | 7 | 3.82 | 0.003785 |
| | GO:0006357~regulation of transcription from RNA polymerase II promoter | 5 | 6.65 | 0.004005 |
| | GO:0051252~regulation of RNA metabolic process | 7 | 3.73 | 0.004244 |
| | GO:0003677~DNA binding | 7 | 3.25 | 0.006735 |
| | GO:0070013~intracellular organelle lumen | 6 | 3.92 | 0.007117 |
| | GO:0010604~positive regulation of macromolecule metabolic process | 5 | 5.64 | 0.007210 |
| | GO:0043233~organelle lumen | 6 | 3.83 | 0.007859 |
| | GO:0008134~transcription factor binding | 4 | 8.44 | 0.007981 |
| | GO:0031974~membrane-enclosed lumen | 6 | 3.76 | 0.008556 |
| | GO:0045893~positive regulation of transcription, DNA-dependent | 4 | 8.10 | 0.009568 |
| | GO:0051254~positive regulation of RNA metabolic process | 4 | 8.04 | 0.009790 |

Table S6 (B): GO term & KEGG pathway enrichment of identified modules in dataset II

| ID | Term and Pathway | Count | Fold Enrichment | P Value |
|----|--|-------|-----------------|----------|
| 7 | hsa04310:Wnt signaling pathway | 3 | 16.84 | 0.008259 |
| | hsa05200:Pathways in cancer | 3 | 7.75 | 0.036417 |
| 8 | GO:0030528~transcription regulator activity | 9 | 3.68 | 0.001150 |
| | GO:0032535~regulation of cellular component size | 4 | 9.51 | 0.007042 |
| 9 | GO:0003700~transcription factor activity | 7 | 6.21 | 0.000314 |
| | GO:0030528~transcription regulator activity | 8 | 4.58 | 0.000468 |
| | GO:0045449~regulation of transcription | 9 | 2.93 | 0.003257 |
| | GO:0006350~transcription | 8 | 3.22 | 0.004387 |
| | GO:0003677~DNA binding | 8 | 2.97 | 0.006288 |
| | GO:0006357~regulation of transcription from RNA polymerase II promoter | 5 | 5.81 | 0.007016 |
| | GO:0006355~regulation of transcription, DNA-dependent | 7 | 3.34 | 0.008751 |
| | GO:0051252~regulation of RNA metabolic process | 7 | 3.26 | 0.009759 |
| | GO:0003700~transcription factor activity | 6 | 6.15 | 0.001198 |
| 10 | GO:0030528~transcription regulator activity | 7 | 4.62 | 0.001223 |
| | GO:0006355~regulation of transcription, DNA-dependent | 7 | 3.82 | 0.003785 |
| | GO:0006357~regulation of transcription from RNA polymerase II promoter | 5 | 6.65 | 0.004005 |
| | GO:0051252~regulation of RNA metabolic process | 7 | 3.73 | 0.004244 |
| | GO:0006350~transcription | 7 | 3.22 | 0.008922 |
| | GO:0045893~positive regulation of transcription, DNA-dependent | 4 | 8.10 | 0.009568 |

Supplementary Figures

Figure S1: Score track of local search for 10 modules




Figure S2: Visualization of identified modules in dataset I: (A) Module 2; (B) Module 3; C) Module 4; (D) Module 5




Figure S3: Visualization of identified modules in dataset I: (A) Module 6; (B) Module 7; (C) Module 8; (D) Module 9




Figure S4: Visualization of modules in dataset II: (A) Module 1; (B) Module 2; (C) Module 3; (D) Module 4; (E) Module 5; (F) Module 6





Figure S5. Visualization of modules in Dataset II: (A) Module 7; (B) Module 8; (C) Module 9; (D) Module 10



References

1. Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L, Kappeler A, Brunner T, Vassella E: **miR-15a and miR-16 Are Implicated in Cell Cycle Regulation in a Rb-Dependent Manner and Are Frequently Deleted or Down-regulated in Non-Small Cell Lung Cancer.** *Cancer Research* 2009, **69**(13):5553-5559.
2. Cho J-H, Gelinas R, Wang K, Etheridge A, Piper M, Batte K, Dakhllallah D, Price J, Bornman D, Zhang S *et al*: **Systems biology of interstitial lung diseases: integration of mRNA and microRNA expression changes.** *BMC Medical Genomics* 2011, **4**(1):8.
3. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C *et al*: **The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities.** *Nature Medicine* 2008, **14**(11):1271-1277.
4. Polytarchou C, Iliopoulos D, Struhl K: **An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state.** *Proceedings of the National Academy of Sciences* 2012, **109**(36):14470-14475.
5. Bhattacharya R, Nicoloso M, Arvizo R, Wang E, Cortez A, Rossi S, Calin GA, Mukherjee P: **MiR-15a and MiR-16 Control Bmi-1 Expression in Ovarian Cancer.** *Cancer Research* 2009, **69**(23):9090-9095.
6. Bandrés E, Cubedo E, Agirre X, Malumbres R, Zárate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzó M *et al*: **Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues.** *Molecular Cancer* 2006, **5**:29-10.
7. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y, Takahashi T: **A Polycistronic MicroRNA Cluster, miR-17-92, Is Overexpressed in Human Lung Cancers and Enhances Cell Proliferation.** *Cancer Research* 2005, **65**(21):9628-9632.
8. Pichiorri F, Suh S-S, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP *et al*: **MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis.** *Proceedings of the National Academy of Sciences* 2008, **105**(35):12885-12890.
9. Abdueva D, Wing M, Schaub B, Triche T, Davicioni E: **Quantitative Expression Profiling in Formalin-Fixed Paraffin-Embedded Samples by Affymetrix Microarrays.** *The Journal of Molecular Diagnostics* 2010, **12**(4):409-417.
10. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S *et al*: **A Mitochondria-K⁺ Channel Axis Is Suppressed in Cancer and Its Normalization Promotes Apoptosis and Inhibits Cancer Growth.** *Cancer cell* 2007, **11**(1):37-51.
11. Lu S., Lee J., Revelo M., Wang X., Lu S., Z. D: **Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.** *Clin Cancer Res* 2007, **13**(19):5692-5702.
12. Oh I.H., E.P. R: **The myb gene family in cell growth, differentiation and apoptosis.** *Oncogene* 1999, **18**(19):3017-3033.
13. H. C: **Genetic regulation of cancer.** *Nature Education* 2008, **1**(1).